Jan 09, 2020: Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).
As per the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options. The strategic alliance will also have access to the targets from the recently formed partnership between Celmatix and Evotec.
Celmatix is the world leader in big data-driven target discovery that focuses on fertility and women’s health. “PCOS is a common, underdiagnosed and undertreated disease among women, with several serious co-morbidities.”
Evotec will receive € 6.5 m direct payment and € 10 m research payments over five years.
In addition, Evotec might be eligible in order to receive pre-clinical, clinical and sales milestones of potentially over € 330 m as well as royalties up to low double-digit percentages of net sales.
In 2012, Bayer and Evotec entered their first strategic five-year, multi-target alliance. The collaboration was productively completed resulting in three clinical and one pre-clinical drug candidate currently advancing during development for the treatment of endometriosis.
A second research alliance was initiated in 2016 to develop multiple clinical candidates for the treatment of kidney diseases. https://www.evotec.com/en/invest/news–announcements/p/bayer-and-evotec-form-new-strategic-alliance-focusing-on-polycystic-ovary-syndrome-5893
